×
CV Sciences Total Long Term Liabilities 2011-2024 | CVSI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CV Sciences total long term liabilities from 2011 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
CV Sciences Total Long Term Liabilities 2011-2024 | CVSI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CV Sciences total long term liabilities from 2011 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$87.5B
Takeda Pharmaceutical (TAK)
$47.5B
Merck (MKGAF)
$24.4B
Astellas Pharma (ALPMY)
$22B
Sandoz Group AG (SDZNY)
$17.6B
Summit Therapeutics (SMMT)
$16.8B
United Therapeutics (UTHR)
$15.6B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.2B
Catalent (CTLT)
$10.9B
Revolution Medicines (RVMD)
$7.7B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4.3B
Dyne Therapeutics (DYN)
$3.7B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Xencor (XNCR)
$1.7B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B